Show simple item record

dc.contributor.authorAloum, Fatima
dc.contributor.authorAl Ayoub, Yuosef
dc.contributor.authorMohammad, Mohammad A.
dc.contributor.authorObeed, Muthana
dc.contributor.authorPaluch, Krzysztof J.
dc.contributor.authorAssi, Khaled H.
dc.date.accessioned2020-08-10T09:03:55Z
dc.date.accessioned2020-08-21T11:09:13Z
dc.date.available2020-08-10T09:03:55Z
dc.date.available2020-08-21T11:09:13Z
dc.date.issued2020-07-15
dc.identifier.citationAloum F, Al Ayoub Y, Mohammad MA et al (2020) Ex vivo and in vitro evaluation of the influence of the inhaler device and formulation on lung deposition of budesonide. Powder Technology. 372: 685-693.en_US
dc.identifier.urihttp://hdl.handle.net/10454/17991
dc.descriptionYesen_US
dc.description.abstractTwo different types of dry powder inhalers (Easyhaler® and RS01®) were used in this work to evaluate the ex vivo and in vitro performance of a budesonide inhaled formulation with recrystallised mannitol, commercial DPI-grade mannitol, or lactose. The aerodynamic performance of the budesonide formulation with recrystallised mannitol was superior when RS01® was used (FPF = 45.8%) compared to Easyhaler® (FPF = 14%). However, the aerodynamic profile was very poor in both devices when commercial mannitol was used. Interestingly, the aerosol performance of the marketed budesonide formulation significantly improved when RS01® was used compared to Easyhaler® (the original device for the formulation). Due to the significant increases in the surface energy of the commercial mannitol formulation, the aerodynamic performance of the formulation was very poor. This work demonstrates the impact of inhaler devices on the performance of inhaled formulations and considers the particle surface energy during formulation development.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttps://doi.org/10.1016/j.powtec.2020.06.037en_US
dc.rights© 2020 Elsevier. Reproduced in accordance with the publisher's self-archiving policy. This manuscript version is made available under the CC-BY-NC-ND 4.0 license (http://creativecommons.org/licenses/by-nc-nd/4.0/)en_US
dc.subjectBudesonide DPI formulation Dry powder inhaler Ex vivo. Surface energy In-Check DIAL Lung depositionen_US
dc.subjectBudesonideen_US
dc.subjectDPI formulationen_US
dc.subjectLung depositionen_US
dc.subjectDry powder inhaleren_US
dc.subjectEx vivoen_US
dc.subjectSurface energyen_US
dc.subjectIn-check DIALen_US
dc.titleEx vivo and in vitro evaluation of the influence of the inhaler device and formulation on lung deposition of budesonideen_US
dc.status.refereedYesen_US
dc.date.Accepted2020-06-11
dc.date.application2020-06-13
dc.typeArticleen_US
dc.date.EndofEmbargo2021-06-14
dc.type.versionAccepted manuscripten_US
dc.description.publicnotesThe full-text of this article will be released for public view at the end of the publisher embargo on 14 Jun 2021.en_US
dc.date.updated2020-08-10T08:04:03Z
refterms.dateFOA2020-08-21T11:09:41Z


Item file(s)

Thumbnail
Name:
POWTEC-D-20-00053R2(2)-accepted.pdf
Size:
1.480Mb
Format:
PDF
Description:
aloum_et_al_2020

This item appears in the following Collection(s)

Show simple item record